Finally, potential added benefits of selected therapies (e.g. breast cancer risk reduction associated with use of raloxifene) have not been formally evaluated.

• 最后，选择治疗的潜在额外好处（如应用雷洛昔芬相关的乳腺癌患病风险降低）也没有正式评估。